| Similar Articles |
 |
Bio-IT World August 13, 2002 Judith S. Hurwitz |
Software for Life Sciences: A Few Requests At the core of the life science revolution is IT. There is a discrepancy, however, between the emerging technology requirements and the preparedness of the technology industry to meet the needs of this market.  |
Chemistry World August 23, 2012 Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.  |
Inc. May 1, 2002 Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...  |
Bio-IT World December 10, 2002 Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.  |
Chemistry World February 2012 |
Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.  |
Bio-IT World September 2006 Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.  |
Finance & Development March 2011 Lora & Pages |
Face-to-Face with Productivity It is not lack of investment but inefficient production that holds back Latin American incomes.  |
Pharmaceutical Executive December 1, 2011 George Baeder |
China's Future in Bioscience Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?  |
Chemistry World December 8, 2011 Sarah Houlton |
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry.  |
Pharmaceutical Executive April 1, 2007 Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.  |
Bio-IT World April 2006 Kevin Davies |
Microsoft Forges BioIT Alliance The software giant's fledgling alliance aims to bring together companies from a cross-section of the industry -- from biotech and Big Pharma to equipment manufacturers and software developers -- to collaborate on technology that will speed drug discovery.  |
Reactive Reports Issue 57 |
Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools.  |
Investment Advisor August 2006 |
S&P Mutual Fund Sector Focus: Health Care Funds Tired and Sluggish Big pharma names dominate most health care funds and these businesses are beset with problems. One of the best longer-term performers in this area, the $561-million Schwab Health Care Fund.  |
Pharmaceutical Executive January 21, 2014 Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?  |
The Motley Fool September 9, 2004 Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.  |
Bio-IT World November 2005 Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value.  |
Bio-IT World September 2005 Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials.  |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies...  |
Bio-IT World June 2006 Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process.  |
Investment Advisor December 2005 Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.  |
Pharmaceutical Executive January 1, 2012 William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.  |
Bio-IT World March 10, 2003 Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together.  |
Pharmaceutical Executive May 1, 2009 |
Bank on IT Tough economic times call for a bold approach to evolving information technology solutions.  |
Bio-IT World October 2006 Thomas G. Morr |
Eight Essential Elements for Commercial Success For life sciences companies both young and old, location is one of the critical success factors. With that in mind, here are eight essential considerations for life sciences executives when they are thinking of starting a business or opening a new location.  |
Pharmaceutical Executive October 1, 2008 RS Kumar |
Evolving Clinical Trials Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in efficiency.  |
IEEE Spectrum January 2012 Philip E. Ross |
Don't Let Innovation Languish The world's economy depends on innovation rates that are faster than they were for most of human history -- and faster than they are today.  |
Bio-IT World December 10, 2002 Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D.  |
The Motley Fool August 2, 2004 Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.  |
Pharmaceutical Executive April 1, 2006 Ron Feemster |
Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials.  |
The Motley Fool November 16, 2006 Jim Fink |
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007.  |
HBS Working Knowledge November 13, 2006 Sean Silverthorne |
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business.  |
The Motley Fool April 4, 2009 Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.  |
The Motley Fool May 5, 2009 Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry.  |
Pharmaceutical Executive December 1, 2010 Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda  |
Pharmaceutical Executive January 1, 2012 Bill Drummy |
Scared to Death The pharma industry's risk-aversion is risking its survival. Where did the courage to innovate go?  |
Knowledge@Wharton October 8, 2003 |
Biosciences: High Risk, High Reward, and the Potential for "Real Chaos" While bioscience researchers struggle to understand the workings of the human body, biotech managers and investors are searching for ways to better understand this complex and quickly evolving industry, according to Wharton faculty and lecturers.  |
Bio-IT World June 15, 2003 Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry  |
Chemistry World January 29, 2013 Laura Howes |
Five green chemical feedstock projects launched The UK's Engineering and Physical Sciences Research Council has announced 10.7 million pounds, in combination with 1.1 million pounds from the Biotechnology and Biological Sciences Research Council, to fund five projects to develop new bio-based feedstocks for the chemical industry.  |
Job Journal August 8, 2004 Rich Heintz |
Biotech's Winning Formula for Steady Job Growth Deep pockets are creating expanding opportunities and biotechnology is helping to put America back to work.  |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.  |
BusinessWeek October 20, 2003 Gary S. Becker |
The Productivity Boom Is Just Warming Up In the past, productivity almost always fell during recessions because both labor and capital were underutilized as output sagged. But the apparent paradox of the past few years is that labor productivity has grown even more rapidly since 2000 than in the '90s.  |
IndustryWeek August 1, 2004 Tonya Vinas |
Making Waves Dubbed the 'third wave' of biotechnology, after medicine and agriculture, industrial biotechnology is promising to reshape manufacturing.  |
Bio-IT World October 14, 2004 Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape.  |
Bio-IT World April 2006 Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed.  |
Finance & Development March 1, 2006 Baily & Farrell |
Breaking Down Barriers to Growth Encouraging competition is key to reviving stalled industrial economies.  |
The Motley Fool April 24, 2007 Ryan Fuhrmann |
Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.  |
The Motley Fool June 21, 2005 Brian Gorman |
Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.  |
The Motley Fool January 20, 2011 Dan Caplinger |
Value Investing Will Never Be the Same More value-oriented funds are buying traditional growth stocks.  |
IndustryWeek January 1, 2005 Patricia Panchak |
Shaping the Future of Manufacturing A tour through manufacturing's recent history reveals clues of what's to come.  |
The Motley Fool December 20, 2007 Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.  |